Press
With two million devices sold, Tasso is now reaching more patients than ever worldwide. Learn how Tasso is making an impact in the infographic below.
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TS Blood Collection Kit, a product of Tasso-SNBL, Ltd., received certification as a controlled medical device under Japan’s Pharmaceuticals and Medical Devices Act. This certification was conducted by a third-party certification body registered with the Ministry of Health, Labour and Welfare (MHLW) and confirms the product’s safety, performance, and quality control system comply with relevant regulations.
Tasso, Inc., a leader in patient-centric blood collection, and SheMed, a UK-based women’s healthcare company, have teamed up to deliver safer, more personalized weight loss treatments through convenient at-home diagnostics. SheMed’s patient-friendly testing program, which integrates the Tasso+ blood collection device, ensures that every patient completes a comprehensive lab screening before starting GLP-1 treatment, all from the comfort of home. The program has already treated thousands of women across the UK.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced new regulatory clearances for the Tasso™ Mini device. Tasso Mini is now licensed with Health Canada and has secured additional approvals in the European Union to expand into Italy and Spain. The new clearances expand Tasso Mini's availability beyond the current U.S. FDA Class II 510(k) clearance and European CE Marking.
Shin Nippon Biomedical Laboratories, Ltd. and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions hereby announce that they have agreed to establish a new joint venture company for exclusive distribution of Tasso’s proprietary on-demand blood collection device in Japan.
2024 was a landmark year for Tasso as we advanced our mission to make diagnostic testing more accessible and enhance the patient experience. With over 1.5 million devices sold, our innovative, patient-centric blood collection technology continues to transform the healthcare industry.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, and ARUP Laboratories, the largest nonprofit clinical and academic reference laboratory in the United States, today announced that they have entered into a partnership to develop and operationalize high-quality, at-home, blood testing services to support clinical research.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful renewal of their SOC 2 Type II compliance certification with an unqualified opinion, also known as a clean report, following a rigorous independent audit. The SOC 2 Type II audit is conducted by independent, third-party auditors to determine whether a company is maintaining enterprise-level data security through its operations, controls, and processes. This renewal highlights Tasso’s continuing commitment to meeting the highest industry standards and demonstrates the company’s ability to securely manage client data.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, surveyed more than 600 adults (age 18-65+) within the United States to assess their experiences and preferences regarding blood testing, as well as their perspectives about the future of patient care. The survey, titled Patient Preferences, Perceptions, and the Evolving Challenges of Ensuring Patient Compliance With Diagnostic Healthcare Testing, validated prevailing industry perspectives that the current status quo for blood collection underserves patients seeking more convenient and less painful options for blood collection.
InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021. In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.
Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a new collaboration that will reduce patient burden in clinical trials requiring blood collection. Lindus Health will adopt Tasso’s virtually painless remote blood collection technology as an option for sponsors looking to enable simple, more cost-effective remote blood collection while conducting their clinical trials. This innovative method will allow participants to collect simple blood samples themselves at home without the need for a mobile phlebotomist or nurse.
The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research. The relationship will combine Tasso’s signature capillary blood collection technology with LLS’ research and focus on patient advocacy, with the goal of improving the oncology patient experience.
The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD). The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s.
Last week we accomplished a huge milestone and shipped our one millionth device. This was an incredible moment for our company as a whole and something that was hard to imagine when we first started out nearly 12 years ago.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.
In 2023, Tasso achieved remarkable growth driven by our unwavering focus on expanding access to care for more patients by offering convenient diagnostic healthcare options. Our patient-centric blood collection solutions have proven to be a valuable addition to the pharmaceutical and healthcare industry. Several new engagements forged in the second half of 2023 support our continued growth and ability to offer more complete solutions to the industry.
Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the UK and Ireland – and Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced a partnership to offer at-home healthcare diagnostic testing powered by Tasso’s innovative blood collection technology.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. The auditors observed Tasso’s operations against all five SOC 2 Trust Services Criteria (Security, Availability, Processing Integrity, Confidentiality, and Privacy) and found no exceptions. This achievement demonstrates Tasso’s ability to securely manage client data and highlights the company’s commitment to meeting the highest industry standards.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the appointment of Monica Williams as Chief Financial Officer, reporting to Tasso’s CEO Ben Casavant.
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.
Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.
Tasso has continued to experience tremendous growth in 2023, fueled by new and expanded partnerships and increased demand for our patient-centric blood collection solutions. With our focus on expanding access to care for more patient populations, accelerating convenient at-home healthcare options and paving the way for a pivotal shift toward decentralized clinical trials, we continued to expand our capabilities and footprint, solidify partnerships and gain market traction.
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.
Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today entered into a collaboration to offer Aptar Digital Health end-users access to Tasso’s devices for blood collection. The collaboration will focus on improving patient care through a simplified and integrated experience, delivering clinical value to patients through a real-world deployment and increasing adoption of new technologies by patients, providers and pharmaceutical companies.
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program. The certification confirms Tasso’s compliance with the standards and regulatory requirements of Australia, Canada and the United States, opening potential new global markets for Tasso.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection technology, today announced the appointment of Duncan Porter as Senior Vice President of Growth, reporting to Tasso’s CEO Ben Casavant. Porter will lead Tasso's international expansion, building upon the recent CE regulatory approval of their TassoOneTM Plus and Tasso-M20 devices.
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TassoOne Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.